NASDAQ · DXR
Healthcare · Medical - Instruments & Supplies
$11.27
Down-$0.20 (-1.78%)
Updated Sep 15, 2026, 11:50 AM
SID Score
4.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 18 trading sessions · Daily adjusted prices
DXR closed at $11.27 after 18 trading sessions, up 10.42% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 14, 2026 | $11.34 | $12.0732 | $10.555 | $11.2664 | 200.58K |
| Sep 11, 2026 | $10.8899 | $11.47 | $10.27 | $11.47 | 69.77K |
| Sep 10, 2026 | $11.09 | $11.24 | $10.43 | $10.84 | 71.31K |
| Sep 9, 2026 | $10.5843 | $11.12 | $10.5843 | $10.85 | 14.97K |
| Sep 8, 2026 | $9.9001 | $10.70 | $9.90 | $10.4601 | 47.71K |
| Sep 4, 2026 | $10.2425 | $10.65 | $10.15 | $10.27 | 6.79K |
| Sep 3, 2026 | $10.58 | $11.11 | $10.002 | $10.5502 | 51.55K |
| Sep 2, 2026 | $10.30 | $10.89 | $10.08 | $10.74 | 25.77K |
| Sep 1, 2026 | $10.50 | $11.00 | $9.95 | $10.90 | 24.45K |
| Aug 31, 2026 | $9.9001 | $10.0793 | $9.9001 | $10.0793 | 872 |
| Aug 28, 2026 | $9.67 | $10.62 | $9.65 | $10.20 | 13.26K |
| Aug 27, 2026 | $9.95 | $10.21 | $9.60 | $9.67 | 13.49K |
| Aug 26, 2026 | $10.00 | $10.025 | $9.5501 | $10.025 | 953.28 |
| Aug 25, 2026 | $10.02 | $10.02 | $9.76 | $10.00 | 1.08K |
| Aug 21, 2026 | $9.97 | $10.15 | $9.9501 | $10.00 | 2.02K |
| Aug 19, 2026 | $10.30 | $10.30 | $10.30 | $10.30 | 201.9 |
| Aug 18, 2026 | $10.13 | $10.2999 | $10.03 | $10.29 | 5.22K |
| Aug 17, 2026 | $10.20 | $10.203 | $10.20 | $10.203 | 2.07K |
The latest Smart Investors Daily articles mentioning DXR.
DXR research
Company profile and research snapshot.
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 17, 2025 | Ascendiant Capital | Buy | — |
| Sep 9, 2024 | Ascendiant Capital | Buy | — |
| Jul 29, 2019 | Maxim Group | Buy | — |
| May 16, 2019 | Ascendiant | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Mar 10, 2026
Daxor Corporation (DXR) IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 March 10, 2026 2:00 PM EDTCompany ParticipantsMichael Feldschuh -...
Benzinga · Feb 24, 2026
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, continues its strategic expansion into the outpatient cardiology market with the opening of a new BVA program at a leading
Benzinga · Feb 10, 2026
Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announced its intention to transition its primary regulatory reporting framework from the Investment Company Act of 1940
Benzinga · Feb 10, 2026
"The strategic decision to transition back to Exchange Act reporting is a financial validation of our focused growth strategy," said Robert Michel, Daxor's Chief Financial Officer. "Daxor has achieved the scale necessary
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DXR.
